There is no doubt that ContraFect Corporation (CFRX) ticks all the boxes.

ContraFect Corporation (NASDAQ: CFRX) stock fell -0.44% on Monday to $0.09 against a previous-day closing price of $0.09. With 22.88 million shares changed hands, the volume of the stock remained heavier than its average volume of 4.14 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.0960 whereas the lowest price it dropped to was $0.0880. The 52-week range on CFRX shows that it touched its highest point at $4.54 and its lowest point at $0.08 during that stretch. It currently has a 1-year price target of $5.00. Beta for the stock currently stands at 0.40.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CFRX was down-trending over the past week, with a drop of -10.30%, but this was down by -13.30% over a month. Three-month performance dropped to -43.02% while six-month performance fell -74.11%. The stock lost -96.29% in the past year, while it has lost -5.63% so far this year. A look at the trailing 12-month EPS for CFRX yields -1.52 with Next year EPS estimates of -1.33. For the next quarter, that number is -0.34. This implies an EPS growth rate of 55.40% for this year and 14.20% for next year. EPS is expected to grow by 12.70% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 42.10%.

Float and Shares Shorts:

At present, 39.33 million CFRX shares are outstanding with a float of 37.42 million shares on hand for trading. On Oct 13, 2022, short shares totaled 0.37 million, which was 0.95% higher than short shares on Sep 14, 2022. In addition to Dr. Roger James Pomerantz F.A.C.P., FACP, M.D. as the firm’s Chairman, CEO & Pres, Mr. Michael Messinger CPA, CPA serves as its Chief Financial Officer.


Institutional Ownership:

Through their ownership of 36.13% of CFRX’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 2.25% of CFRX, in contrast to 18.62% held by mutual funds. Shares owned by individuals account for 0.33%. As the largest shareholder in CFRX with 4.04% of the stake, Acadian Asset Management LLC holds 1,588,806 shares worth 1,588,806. A second-largest stockholder of CFRX, Invus Public Equities Advisors LL, holds 1,500,000 shares, controlling over 3.81% of the firm’s shares. The Vanguard Group, Inc. is the third largest shareholder in CFRX, holding 629,499 shares or 1.60% stake. With a 1.08% stake in CFRX, the Vanguard Extended Market Index Fu is the largest stakeholder. A total of 423,968 shares are owned by the mutual fund manager. The Fidelity Extended Market Index Fu, which owns about 0.46% of CFRX stock, is the second-largest Mutual Fund holder. It holds 182,668 shares valued at 17536.0. iShares Tr. – Micro Cap ETF holds 0.21% of the stake in CFRX, owning 81,976 shares worth 7870.0.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CFRX since 1 analysts follow the stock currently. There are 0 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With CFRX analysts setting a high price target of $3.00 and a low target of $3.00, the average target price over the next 12 months is $3.00. Based on these targets, CFRX could surge 3233.33% to reach the target high and rise by 3233.33% to reach the target low. Reaching the average price target will result in a growth of 3233.33% from current levels.


EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. CFRX will report FY 2022 earnings on 03/21/2024. Analysts have provided yearly estimates in a range of -$1.55 being high and -$1.55 being low. For CFRX, this leads to a yearly average estimate of -$1.55. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. ContraFect Corporation surprised analysts by -$0.20 when it reported -$0.43 EPS against a consensus estimate of -$0.23. The surprise factor in the prior quarter was -$0.13. Based on analyst estimates, the high estimate for the next quarter is -$0.34 and the low estimate is -$0.34. The average estimate for the next quarter is thus -$0.34.

Summary of Insider Activity:

Insiders traded CFRX stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has remained unchanged to 0 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 0 while 0 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *